A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects

Inclusion criteria

• Healthy, as judged by the investigator or sub-investigator based on the results of physical examinations and all tests
• Body weight: male: ≥45.0 kg, <85.0 kg; female: ≥40.0 kg, <75.0 kg
• BMI (at screening): ≥17.6, <30.0

Exclusion criteria

• Use of any other investigational drug in another clinical study or a post-marketing clinical study within 120 days before the administration of the study drug
• Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days, or blood components within 14 days before the screening assessment.
• Any surgical intervention (including tooth extraction) or trauma within 90 days before hospitalization until the administration, or plan of any surgical intervention within 10 week after the final administration
• A deviation from the normal reference range of blood pressure, pulse rate, body temperature, or 12-lead ECG
• PT or aPTT on blood coagulation tests outside the upper or lower reference limits (PT: 9.9 to 15.4 sec.; aPTT: 22.5 to 49.5 sec.)
• Upper gastrointestinal disease (e.g. nausea, vomiting, stomachache) within 7 days before the study
• Concurrent or previous hepatic disease (e.g. viral hepatitis, drug-induced liver injury)
• Concurrent or previous heart disease (e.g. congestive heart failure, angina pectoris, arrhythmia requiring treatment)
• Concurrent or previous respiratory disease (e.g. serious bronchial asthma, chronic bronchitis; except for a history of childhood asthma)
• Concurrent or previous renal disease (e.g. acute renal failure, glomerulonephritis, interstitial nephritis; except for a history of calculus)
• Concurrent or previous malignant tumor
• Excessive smoking or drinking habit [measure of "excessive": alcohol: average 45 g/day (a 633 mL bottle of beer contains 25 g of alcohol, and 180 mL of Japanese sake contains 22 g of alcohol), smoking: average 20 cigarettes/day]
• Previous treatment with YM150